What are ImmunityBio, Inc.'s total assets?

ImmunityBio, Inc. (IBRX) holds $646.6M in total assets, up 112.9% year over year.

How much debt does ImmunityBio, Inc. have?

ImmunityBio, Inc. carries $445.4M in total debt against -$870.0M of shareholders' equity, a debt-to-equity ratio of 0.11.

How much cash does ImmunityBio, Inc. have?

ImmunityBio, Inc. holds $205.2M in cash and equivalents.

Can ImmunityBio, Inc. cover its short-term obligations?

Its current ratio is 6.67 — current assets exceed current liabilities.

Where does ImmunityBio, Inc.'s balance sheet data come from?

Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ImmunityBio, Inc. IBRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$205.19M+132%	$88.33M+46.6%	$60.24M-56.2%	$137.66M+127%	$60.66M-57.7%
Short-term investments	$175.69M+13.7%	$154.48M-21.8%	$197.57M+1,135%	$16M+1,619%	$931K-85.4%
Restricted cash	——	——	——	——	——
Accounts receivable, net	$139.98M+23.1%	$113.74M+54.7%	$73.53M+60.9%	$45.69M+85.8%	$24.6M+225%
Inventories	$45.71M+29.5%	$35.3M+62.0%	$21.79M+27.8%	$17.04M+39.5%	$12.21M+224%
Work in process	$17.43M+39.1%	$12.52M+182%	$4.43M-24.1%	$5.84M-22.2%	$7.51M—
Finished goods	$1.98M+4.3%	$1.89M-16.5%	$2.27M+183%	$801K-14.5%	$937K—
Total current assets	$452.95M+43.9%	$314.88M-4.4%	$329.5M+58.3%	$208.13M+90.7%	$109.16M-40.9%
Property and equipment, net	$112.79M-1.3%	$114.26M-11.8%	$129.6M-2.6%	$133M-1.7%	$135.27M-1.3%
Accumulated depreciation	$115.75M+2.9%	$112.49M+3.0%	$109.25M+3.2%	$105.87M+2.9%	$102.94M+3.4%
Operating lease right-of-use assets	11.1%0.0%	11.1%0.0%	11.1%-0.7%	11.8%+0.8%	11%-3,336,299,989%
Goodwill	$910K0.0%	$910K0.0%	$910K0.0%	$910K—	——
Intangible assets, net	$11.91M-8.3%	$12.99M—	——	——	——
Total assets	$646.64M+28.8%	$501.9M-3.3%	$518.99M+29.1%	$402.08M+32.4%	$303.76M-20.7%
Accrued expenses	$48.2M+2.9%	$46.84M+7.4%	$43.6M+22.1%	$35.71M+28.0%	$27.89M-31.3%
Accrued compensation	$7.33M+28.1%	$5.72M-20.5%	$7.2M-10.3%	$8.03M+37.0%	$5.86M+25.2%
Current portion of long-term debt	$53K—	——	——	——	——
Operating lease liabilities, current	$7.63M+1.2%	$7.54M+3.0%	$7.32M-1.0%	$7.39M-0.9%	$7.46M-0.1%
Finance Lease Liability, Current	——	——	——	——	——
Derivative liabilities	$23.31M+18.2%	$19.72M+7.6%	$18.32M-1.6%	$18.61M-9.4%	$20.54M-21.4%
Total current liabilities	$67.95M+10.0%	$61.75M+8.1%	$57.13M+12.8%	$50.64M+2.9%	$49.21M-10.4%
Long-term debt	$404.3M+24.5%	$324.62M+2.7%	$316.15M+3.0%	$307.05M+3.6%	$296.29M+4.2%
Operating lease liabilities, non-current	$33.15M-0.9%	$33.45M-2.0%	$34.13M-4.8%	$35.84M+8.3%	$33.1M-5.0%
Finance Lease Liabilities (Total)	$266K—	——	——	——	——
Operating Lease Liabilities (Total)	$40.77M-0.5%	$40.98M-1.1%	$41.45M+6,808%	$600K-98.5%	$40.56M-4.1%
Finance lease liabilities	$213K—	——	——	——	——
Other non-current liabilities	$472K+11.3%	$424K-39.6%	$702K-1.1%	$710K+91.9%	$370K+16.0%
Total liabilities	$1.52B+51.4%	$1B-3.9%	$1.04B+7.3%	$971.9M+8.7%	$894.24M+2.7%
Common stock	1.7B0.0%	1.7B+22.2%	1.4B0.0%	1.4B0.0%	1.4B+1,588,135%
Additional paid-in capital	$3.46B+8.3%	$3.2B+2.0%	$3.14B+4.0%	$3.01B+4.2%	$2.89B+0.3%
Retained earnings	-$4.36B-17.0%	-$3.73B-1.7%	-$3.66B-1.9%	-$3.6B-2.6%	-$3.5B-3.8%
Accumulated other comprehensive income (loss)	$27.45M-5.2%	$28.96M+479%	$5M-60.2%	$12.57M-37.0%	$19.96M+1,566%
Treasury stock	163.8K0.0%	163.8K0.0%	163.8K0.0%	163.8K0.0%	163.8K0.0%
Noncontrolling interests	$880K-1.7%	$895K-1.5%	$909K-2.3%	$930K-2.0%	$949K-2.1%
Total stockholders' equity	-$870.01M-73.8%	-$500.47M+4.5%	-$524.32M+8.1%	-$570.75M+3.5%	-$591.43M-20.9%
Total liabilities and stockholders' equity	$646.64M+28.8%	$501.9M-3.3%	$518.99M+29.1%	$402.08M+32.4%	$303.76M-20.7%
Allowance for Doubtful Accounts	$2.5M+25.0%	$2M—	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	$2.5M+25.0%	$2M—	——	——	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$206.47M+131%	$89.43M+45.8%	$61.34M-55.6%	$138.14M+126%	$61.14M-57.5%
Finished goods	$1.98M+4.3%	$1.89M-16.5%	$2.27M+183%	$801K-14.5%	$937K—
Short- term Investments	$175.69M+13.7%	$154.48M-21.8%	$197.57M+1,135%	$16M+1,619%	$931K-85.4%
Other current assets	$3.02M+41.6%	$2.14M-15.0%	$2.51M+53.0%	$1.64M-30.2%	$2.35M+80.6%
Other Inventory, Net	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——	——
Finite Lived Intangible Assets - Gross	——	——	——	——	——
Goodwill and Intangible Assets, Net	$12.89M-7.7%	$13.95M-3.6%	$14.48M-3.4%	$14.98M—	——
Indefinite-Lived Intangible Assets	$62K+19.2%	$52K+44.4%	$36K-93.5%	$553K+8.4%	$510K+4.3%
Indefinite-Lived Intangible Assets, Gross	$62K+19.2%	$52K+44.4%	$36K-93.5%	$553K+8.4%	$510K+4.3%
Indefinite-Lived Research and Development Assets	$62K+19.2%	$52K+44.4%	$36K-93.5%	$553K+8.4%	$510K+4.3%
Indefinite-Lived Trademarks	$62K+19.2%	$52K+44.4%	$36K-93.5%	$553K+8.4%	$510K+4.3%
Net Investment in Lease	$33.03M+0.1%	$33.01M-0.6%	$33.2M-4.4%	$34.72M+9.3%	$31.78M-4.7%
Convertible note receivable	$0-100%	$7.38M+0.9%	$7.32M+0.9%	$7.25M+0.9%	$7.19M+0.9%
Intangible assets — net	$11.91M-8.3%	$12.99M—	——	——	——
Goodwill and intangible assets, net	$12.89M-7.7%	$13.95M-3.6%	$14.48M-3.4%	$14.98M—	——
Operating lease right-of-use assets	$33.03M+0.1%	$33.01M-0.6%	$33.2M-4.4%	$34.72M+9.3%	$31.78M-4.7%
Property, plant and equipment at cost	$228.53M+0.8%	$226.75M-5.1%	$238.85M0.0%	$238.88M+0.3%	$238.21M+0.6%
Operating Lease Right-of-Use Assets in Other Assets	$33.03M+0.1%	$33.01M-0.6%	$33.2M-4.4%	$34.72M+9.3%	$31.78M-4.7%
Accrued liabilities and other current	$48.2M+2.9%	$46.84M+7.4%	$43.6M+22.1%	$35.71M+28.0%	$27.89M-31.3%
Accrued Marketing and Advertising Expenses	$8.07M+27.9%	$6.31M+2.7%	$6.15M—	——	——
Other Commercial Liabilities	$48.2M+2.9%	$46.84M+7.4%	$43.6M+22.1%	$35.71M+28.0%	$27.89M-31.3%
Accrued Liabilities, Current	$48.2M+2.9%	$46.84M+7.4%	$43.6M+22.1%	$35.71M+28.0%	$27.89M-31.3%
Derivative Liabilities - Fair Value	$23.31M+18.2%	$19.72M+7.6%	$18.32M-1.6%	$18.61M-9.4%	$20.54M-21.4%
Finance Lease Liability Payment Due	——	——	——	——	——
Finance Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Lease Liability Payments - 2021	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Due Year Five	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Professional Service Fees Payable	$12.25M+63.0%	$7.51M-3.7%	$7.8M-9.1%	$8.59M+5.8%	$8.12M-51.8%
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2029 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due After Year Five	——	——	——	——	——
Operating Lease Liability Payments - Thereafter (Lessee)	——	——	——	——	——
Marketing and selling	$8.07M+27.9%	$6.31M+2.7%	$6.15M—	——	——
Total debt	$445.39M+21.7%	$365.93M+2.2%	$357.93M+16.2%	$308M-8.6%	$336.84M+3.1%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	1B+3.5%	1B+2.7%	985M+7.6%	915.6M+7.3%	853.6M+0.1%
Common Stock Shares Outstanding	$77.07M+453,271%	$17K-34.6%	$26K-13.3%	$30K-65.5%	$87K-3.3%
Additional paid-in capital	$3.46B+8.3%	$3.2B+2.0%	$3.14B+4.0%	$3.01B+4.2%	$2.89B+0.3%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$104K+3.0%	$101K+3.1%	$98K+7.7%	$91K+7.1%	$85K0.0%
Number of Exercisable Options	——	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	23.4M-2.4%	23.9M-1.9%	24.4M-5.9%	25.9M+1.9%	25.5M+65.2%
Warrants and Rights Outstanding	47.9M-26.4%	65.1M0.0%	65.1M+83.6%	35.4M+454%	6.4M0.0%
Weighted Average Exercise Price of Outstanding Options	$4.98+0.2%	$4.970.0%	$4.97-18.4%	$6.09-1.5%	$6.18-22.8%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——	——
Cumulative Cost Basis	$228.53M+0.8%	$226.75M-5.1%	$238.85M0.0%	$238.88M+0.3%	$238.21M+0.6%
Accrued bonuses	$3.93M-72.6%	$14.35M+39.3%	$10.3M+46.1%	$7.05M+92.1%	$3.67M-64.5%
Accrued preclinical and clinical trial costs	$10.26M+86.8%	$5.49M+21.4%	$4.52M+22.5%	$3.69M+17.1%	$3.15M+9.6%
Professional service fees	$12.25M+63.0%	$7.51M-3.7%	$7.8M-9.1%	$8.59M+5.8%	$8.12M-51.8%
Accrued research and development costs	$3.04M+15.3%	$2.64M-9.6%	$2.91M+6.1%	$2.75M+20.9%	$2.27M-24.3%
Allowance for doubtful accounts	$2.5M+25.0%	$2M—	——	——	——
Cash and cash equivalents, end of period	$206.47M+131%	$89.43M+45.8%	$61.34M-55.6%	$138.14M+126%	$61.14M-57.5%
Class of Warrant or Right, Outstanding	$47.86M-26.4%	$65.05M0.0%	$65.05M+83.6%	$35.42M+454%	$6.4M0.0%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$1.65B0.0%	$1.65B+22.2%	$1.35B0.0%	$1.35B0.0%	$1.35B0.0%
Common stock, shares issued (in shares)	$1.05B+3.5%	$1.01B+2.7%	$984.97M+7.6%	$915.63M+7.3%	$853.56M+0.1%
Common Stock, Shares, Outstanding	$1.05B+3.5%	$1.01B+2.7%	$984.97M+7.6%	$915.63M+7.3%	$853.56M+0.1%
Short-term debt and current portion of long-term debt	——	——	——	——	——
Current maturities of long-term debt	$53K—	——	——	——	——
Finance Lease Liability Payments Due	——	——	——	——	——
Finance Lease Liability Payments Due After Year Five	——	——	——	——	——
2027	——	——	——	——	——
Finance Lease Liability Payments Due Year Five	——	——	——	——	——
Finance Lease Liability Payments Due Year Four	——	——	——	——	——
Finance Lease Liability Payments Due Year Three	——	——	——	——	——
Finance Lease Liability Payments Due Year Two	——	——	——	——	——
Finance Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$256K—	——	——	——	——
Thereafter	——	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$9.03M+13.4%	$7.96M+7.2%	$7.42M+7.8%	$6.88M+8.0%	$6.38M+8.7%
2028	——	——	——	——	——
2030	——	——	——	——	——
Remainder of 2026	——	——	——	——	——
2027	——	——	——	——	——
2029	——	——	——	——	——
Gross Carrying Amount	——	——	——	——	——
Goodwill, Gross	$910K0.0%	$910K0.0%	$910K0.0%	$910K—	——
Trademarks	$62K+19.2%	$52K+44.4%	$36K-93.5%	$553K+8.4%	$510K+4.3%
IPR&D, gross	$62K+19.2%	$52K+44.4%	$36K-93.5%	$553K+8.4%	$510K+4.3%
Indefinite Lived Intangible Assets, Gross, Including Goodwill	$972K+1.0%	$962K+1.7%	$946K-35.3%	$1.46M—	——
Indefinite-Lived Intangible Assets, Net of Accumulated Impairment	$972K+1.0%	$962K+1.7%	$946K-35.3%	$1.46M—	——
Insurance premium financing asset	$884K-49.5%	$1.75M-32.7%	$2.6M—	$0-100%	$315K-74.8%
Intangible Assets, Gross (Including Goodwill)	——	——	——	——	——
Inventory on hand	——	——	——	——	——
Lease, Right-Of-Use Asset	$33.29M—	——	——	——	——
Lessee, Lease Liability	$41.04M—	——	——	——	——
Lessee, Lease Liability, to be Paid	——	——	——	——	——
Lessee, Lease Liability, to be Paid, After Year Five	——	——	——	——	——
Lessee, Lease Liability, to be Paid, Remainder of Fiscal Year	——	——	——	——	——
Lessee, Lease Liability, to be Paid, Year Five	——	——	——	——	——
Lessee, Lease Liability, to be Paid, Year Four	——	——	——	——	——
Lessee, Lease Liability, to be Paid, Year One	——	——	——	——	——
Lessee, Lease Liability, to be Paid, Year Three	——	——	——	——	——
Lessee, Lease Liability, to be Paid, Year Two	——	——	——	——	——
Lessee, Lease Liability, Undiscounted Excess Amount	——	——	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Noncontrolling interests in subsidiaries	$880K-1.7%	$895K-1.5%	$909K-2.3%	$930K-2.0%	$949K-2.1%
Operating Lease Weighted Average Discount Rate Percent	$0.110.0%	$0.110.0%	$0.11-5.9%	$0.12+7.3%	$0.11+11.1%
Other accrued liabilities	$2.45M-20.3%	$3.07M+45.2%	$2.12M+8.9%	$1.94M-26.7%	$2.65M+152%
Prepaid equipment maintenance	$1.09M-4.4%	$1.14M-10.2%	$1.27M-18.1%	$1.55M+0.1%	$1.54M+6.6%
Prepaid Insurance	$1.45M-20.5%	$1.83M+19.4%	$1.53M+7.5%	$1.42M-34.2%	$2.16M+5.1%
Prepaid rent	$1.63M+10.3%	$1.47M-0.1%	$1.48M+1.2%	$1.46M-4.8%	$1.53M—
Prepaid research and development costs	$6.31M-33.9%	$9.54M-2.0%	$9.73M+21.5%	$8.01M+40.6%	$5.7M-2.0%
Prepaid services	$9.52M+34.6%	$7.07M-8.7%	$7.75M-3.9%	$8.06M+49.7%	$5.39M-30.6%
Prepaid software license fees	$4.36M+21.2%	$3.59M-18.3%	$4.4M+30.9%	$3.36M+25.1%	$2.68M-0.1%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$23.36M-2.4%	$23.93M-1.9%	$24.4M-5.9%	$25.93M+1.9%	$25.46M+65.2%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$4.98+0.2%	$4.970.0%	$4.97-18.4%	$6.09-1.5%	$6.18-22.8%
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$77.07M+453,271%	$17K-34.6%	$26K-13.3%	$30K-65.5%	$87K-3.3%
Treasury stock, shares (in shares)	$163.8K0.0%	$163.8K0.0%	$163.8K0.0%	$163.8K0.0%	$163.8K0.0%
Warrants And Rights Outstanding	$308.19M+265%	$84.42M-26.7%	$115.16M+72.0%	$66.96M+642%	$9.02M+5.2%
Purchase Obligation	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——	——
Weighted-Average Discount Rate	11.6%—	——	——	——	——
Weighted-Average Discount Rate - Finance Leases	$0.12—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about ImmunityBio, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are ImmunityBio, Inc.'s total assets?: ImmunityBio, Inc. (IBRX) holds $646.6M in total assets, up 112.9% year over year.
How much debt does ImmunityBio, Inc. have?: ImmunityBio, Inc. carries $445.4M in total debt against -$870.0M of shareholders' equity, a debt-to-equity ratio of 0.11.
How much cash does ImmunityBio, Inc. have?: ImmunityBio, Inc. holds $205.2M in cash and equivalents.
Can ImmunityBio, Inc. cover its short-term obligations?: Its current ratio is 6.67 — current assets exceed current liabilities.
Where does ImmunityBio, Inc.'s balance sheet data come from?: Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.